Holen Sie sich die Stockscreener-App
23.77
34.98%
6.16
Handel nachbörslich:
23.57
-0.20
-0.84%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SRPT?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$17.61
Offen:
$19.76
24-Stunden-Volumen:
17.01M
Relative Volume:
5.94
Marktkapitalisierung:
$2.50B
Einnahmen:
$2.20B
Nettoeinkommen (Verlust:
$-842.79M
KGV:
-2.817
EPS:
-8.4382
Netto-Cashflow:
$-332.39M
1W Leistung:
+38.52%
1M Leistung:
+25.30%
6M Leistung:
+34.14%
1J Leistung:
-67.71%
1-Tages-Spanne:
$19.67
$23.85
1-Wochen-Bereich:
$16.45
$23.85
52-Wochen-Spanne:
$10.41
$74.40
Sarepta Therapeutics Inc Stock (SRPT) Company Profile
Firmenname
Sarepta Therapeutics Inc
Sektor
Branche
Telefon
617-274-4000
Adresse
215 FIRST STREET, CAMBRIDGE, MA
Compare SRPT vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SRPT
Sarepta Therapeutics Inc
|
23.77 | 1.85B | 2.20B | -842.79M | -332.39M | -8.4382 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-28 | Fortgesetzt | Barclays | Equal Weight |
| 2025-12-09 | Eingeleitet | Wedbush | Outperform |
| 2025-11-05 | Hochstufung | Mizuho | Neutral → Outperform |
| 2025-09-22 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2025-07-29 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2025-07-29 | Eingeleitet | Bernstein | Mkt Perform |
| 2025-07-29 | Bestätigt | H.C. Wainwright | Sell |
| 2025-07-29 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2025-07-29 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-07-28 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2025-07-25 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2025-07-24 | Eingeleitet | Citigroup | Sell |
| 2025-07-23 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2025-07-22 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-07-21 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2025-07-21 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-07-21 | Herabstufung | Mizuho | Outperform → Neutral |
| 2025-07-21 | Herabstufung | Needham | Hold → Underperform |
| 2025-07-21 | Herabstufung | UBS | Buy → Neutral |
| 2025-07-18 | Herabstufung | Needham | Buy → Hold |
| 2025-06-20 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-06-18 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-06-17 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-06-16 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2025-06-16 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-06-16 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-06-16 | Herabstufung | H.C. Wainwright | Neutral → Sell |
| 2025-06-16 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-06-16 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-06-06 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
| 2025-05-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2025-04-11 | Eingeleitet | Wells Fargo | Overweight |
| 2025-04-02 | Hochstufung | H.C. Wainwright | Sell → Neutral |
| 2025-03-31 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Hold |
| 2024-11-27 | Bestätigt | Needham | Buy |
| 2024-11-25 | Eingeleitet | H.C. Wainwright | Sell |
| 2024-11-07 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2024-10-21 | Eingeleitet | Jefferies | Buy |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-07-29 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-06-26 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-05-31 | Eingeleitet | Piper Sandler | Overweight |
| 2024-05-28 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-05-14 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-01-31 | Eingeleitet | BMO Capital Markets | Outperform |
| 2023-12-13 | Fortgesetzt | Citigroup | Buy |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-11-21 | Eingeleitet | Wedbush | Outperform |
| 2023-10-31 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-31 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-06-23 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-04-26 | Eingeleitet | SMBC Nikko | Outperform |
| 2023-04-04 | Eingeleitet | Citigroup | Buy |
| 2023-03-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-12-22 | Bestätigt | BTIG Research | Buy |
| 2022-12-16 | Hochstufung | UBS | Neutral → Buy |
| 2022-04-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2022-01-05 | Bestätigt | Needham | Buy |
| 2021-12-09 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-11-05 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-09-15 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-08-05 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Neutral |
| 2021-01-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-01-11 | Herabstufung | UBS | Buy → Neutral |
| 2021-01-08 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2021-01-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-01-08 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | Eingeleitet | Berenberg | Hold |
| 2020-10-28 | Eingeleitet | UBS | Buy |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-08-20 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2020-03-31 | Eingeleitet | Mizuho | Buy |
| 2019-11-01 | Eingeleitet | Guggenheim | Buy |
| 2019-08-21 | Bestätigt | Needham | Buy |
| 2019-07-09 | Bestätigt | Morgan Stanley | Overweight |
| 2019-07-01 | Bestätigt | RBC Capital Mkts | Outperform |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-11 | Bestätigt | Credit Suisse | Outperform |
| 2018-10-12 | Eingeleitet | Bernstein | Outperform |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-26 | Bestätigt | RBC Capital Mkts | Outperform |
| 2018-09-14 | Fortgesetzt | BofA/Merrill | Buy |
| 2018-09-06 | Eingeleitet | Credit Suisse | Outperform |
| 2018-08-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-06-21 | Bestätigt | Robert W. Baird | Outperform |
| 2018-06-20 | Bestätigt | Needham | Buy |
| 2018-06-19 | Bestätigt | H.C. Wainwright | Buy |
Alle ansehen
Sarepta Therapeutics Inc Aktie (SRPT) Neueste Nachrichten
Crude Oil Moves Lower; Cintas Raises FY2026 Forecast - Benzinga
Sarepta Stock Surges 30% After Gene Therapy Trials. The Safety Debate Is Far From Over. - Barron's
Traders Purchase Large Volume of Sarepta Therapeutics Call Options (NASDAQ:SRPT) - MarketBeat
Market movers: Sarepta Therapeutics, Chewy, Merck, Cognyte Software… - Proactive financial news
Wednesday's session: top gainers and losers - ChartMill
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Sarepta Therapeutics (SRPT) Stock Climbs Following Positive siRNA Muscular Dystrophy Trial Results - MEXC
Sarepta Therapeutics, Inc. (SRPT) Discusses Preliminary Phase I/II Data for SRP-1001 in FSHD1 and SRP-1003 in DM1Slideshow (NASDAQ:SRPT) 2026-03-25 - Seeking Alpha
Sarepta Stock Surges 29% After Gene Therapy Trials. The Safety Debate Is Far From Over. - Barron's
Sarepta (SRPT) Sees Promising Phase 1/2 Results in Neuromuscular Treatment - GuruFocus
Sarepta Therapeutics (NASDAQ:SRPT) Shares Gap UpTime to Buy? - MarketBeat
Sarepta sees early success with RNAi drugs from Arrowhead - BioPharma Dive
Sarepta Therapeutics’ experimental siRNA therapies show promising early results - Proactive financial news
Which stocks are gapping on Wednesday? - ChartMill
Why Is Sarepta Therapeutics Stock Exploding Today? - Benzinga
Sarepta Therapeutics (SRPT) Surges 25% on Promising Trial Data - GuruFocus
SRPT: SRP-1001 and SRP-1003 show potent gene knockdown and safety, advancing toward phase III trials - TradingView
Sarepta (SRPT) Reveals Mixed Results in siRNA Programs for Neuro - GuruFocus
Sarepta Therapeutics shares rise on early promise for rare disease drugs - statnews.com
Sarepta (SRPT) Stock: Rises on Early siRNA Trial Data for Muscular Dystrophy Programs - CoinCentral
Sarepta posts data for muscular dystrophy drugs (SRPT:NASDAQ) - Seeking Alpha
Sarepta Therapeutics Zooms 20% Higher on Promising Clinical Data: Is SRPT Ready for a Bigger Breakout? - 24/7 Wall St.
Sarepta stock surges 14% on early siRNA trial data By Investing.com - Investing.com Canada
Sarepta shares early trial data for two rare disease therapies - Investing.com
SRPT Stock Rallies After Promising Early Results For RNA Therapies Targeting Rare Muscle Diseases - Stocktwits
Sarepta announces first clinical data from sirna pipeline targeting FSHD1 and DM1 - marketscreener.com
Sarepta shares early clinical data from siRNA treatments for rare diseases - StreetInsider
Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1 - Sarepta Therapeutics
Sarepta Urges Full Fed. Circ. To Wipe Out Gene Therapy IP - Law360
Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1 - Sarepta Therapeutics
Sarepta plans to seek full FDA approval of 2 Duchenne treatments - Muscular Dystrophy News
Sarepta Therapeutics: A $2B Business Priced Like It’s Broken (NASDAQ:SRPT) - Seeking Alpha
FDA seeks feedback on voucher program; Study data lift ‘overhang’ on Insmed shares - BioPharma Dive
Sarepta Therapeutics, Inc. (SRPT) Stock Price, News, Quote & History - Yahoo! Finance Canada
How FDA Review of Sarepta’s ESSENCE Data At Sarepta Therapeutics (SRPT) Has Changed Its Investment Story - Yahoo Finance
Sarepta to soon submit SNDAs for traditional approval for Duchenne treatments - MSN
SRPT Stock Price, Quote & Chart | SAREPTA THERAPEUTICS INC (NASDAQ:SRPT) - ChartMill
SRPT stock up as enrollment begins in DMD gene therapy safety study - MSN
Sarepta to request FDA for traditional approvals for Duchenne drugs - MSN
Sarepta plans FDA filings seeking full approval for two DMD therapies - MSN
Sarepta Plans FDA Filings Seeking Full Approval for Two DMD Therapies - Yahoo Finance
Neuromuscular Disease Therapeutics Market to Reach US$45.62 - openPR.com
Sarepta Shares Rise As Company Begins Enrollment In Gene Therapy Safety Enhancement Study - Stocktwits
MDA 2026: ‘Body of evidence for Elevidys continues to grow’ - Muscular Dystrophy News
Sarepta’s Plans To Seek Traditional Approval For DMD Therapies ‘Positive,’ Says Wall Street Analyst - Stocktwits
Sarepta cleared to re-submit sNDAs for Amondys and Vyondys - The Pharma Letter
Sarepta To Request FDA For Traditional Approvals For Duchenne Drugs - Benzinga
Sarepta (SRPT) sNDA Filing Indicates Positive Outlook - GuruFocus
Oppenheimer Reiterates "Outperform" Rating for Sarepta Therapeutics (SRPT) | SRPT Stock News - GuruFocus
Sarepta Therapeutics (NASDAQ:SRPT) Earns Outperform Rating from Oppenheimer - MarketBeat
Sarepta Plans FDA Run for Duchenne Exon Skippers Despite Confirmatory Trial Failure - BioSpace
Finanzdaten der Sarepta Therapeutics Inc-Aktie (SRPT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):